CoChat

Anastrozole Increases Predicted Adult Height of Short Adolescent Males Treated with Growth Hormone: A Randomized, Placebo-Controlled, Multicenter Trial for One to Three Years

Open access
Mauras, Nelly, Gonzalez de Pijem, Lilliam, Hsiang, Helen Y., Desrosiers, Paul, Rapaport, Robert, Schwartz, I. David, Klein, Karen Oerter, Singh, Ravinder J., Miyamoto, Anna, Bishop, Kim · 2008 · The Journal of Clinical Endocrinology & Metabolism
Cited by 151

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Context: The process of epiphyseal fusion during puberty is regulated by estrogen, even in males. Objective: Our objective was to investigate whether anastrozole, a potent aromatase inhibitor, could delay bone age acceleration and increase predicted adult height in adolescent boys with GH deficiency. Methods: Fifty-two adolescent males with GH deficiency treated with GH were randomized to cotreatment with anastrozole or placebo daily for up to 36 months. Results: Fifty subjects completed 12 months, 41 completed 24 months, and 28 completed 36 months. Linear growth was comparable between groups; however, there was a significantly slower increase in bone age advancement from baseline in the anastrozole group vs. placebo group after 2 yr (+1.8 ± 0.1 vs. +2.7 ± 0.1 yr, P < 0.0001) and after 3 yr (+2.5 ± 0.2 vs. +4.1 ± 0.1 yr, P < 0.0001). This resulted in a net increase in predicted adult height of +4.5 ± 1.2 cm in the anastrozole group at 24 months and +6.7 ± 1.4 cm at 36 months as compared with a 1-cm gain at both time points in the placebo group. Estradiol and estrone concentrations increased less in the anastrozole group compared with placebo group. All boys on the aromatase inhibitor had normal tempo of virilization. Safety data, including glucose, and plasma lipid concentrations were comparable between groups. Conclusions: Anastrozole increases adult height potential of adolescent boys on GH therapy while maintaining normal pubertal progression after 2–3 yr. This treatment offers an alternative in promoting growth in GH-deficient boys in puberty. Long-term follow up is needed to elucidate fully the safety and efficacy of this approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2007-1559

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 39

  1. Mauras, 2000, High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial., J Clin Endocrinol Metab, 85, 3653
  2. Mericq, 2000, Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone- releasing hormone analog: results of a prospective, randomized trial., J Clin Endocrinol Metab, 85, 569
  3. Cassorla, 1997, Effects of luteinizing hormone-releasing hormone analog-induced pubertal delay in growth hormone (GH)-deficient children treated with GH: preliminary results., J Clin Endocrinol Metab, 82, 3989
  4. Cara, 1992, Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone., J Pediatr, 120, 709, 10.1016/S0022-3476(05)80232-X · DOI
  5. Reiter, 2006, A brief review of the addition of gonadotropin-releasing hormone agonists (GnRH-Ag) to growth hormone (GH) treatment of children with idiopathic growth hormone deficiency: previously published studies from America, Mol Cell Endocrinol, 254
  6. Pasquino, 2000, Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone., J Clin Endocrinol Metab, 85, 619, 10.1210/jcem.85.2.6387 · DOI
  7. Balducci, 1995, Adult height in short normal adolescent girls treated with GnRHa and GH., J Clin Endocrinol Metab, 80, 3596
  8. Lanes, 1998, Final height after combined growth hormone and gonadotropin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty., Clin Endocrinol (Oxf), 49, 197, 10.1046/j.1365-2265.1998.00499.x · DOI
  9. Gunther, 2000, The effects of the estrogen receptor blocker, Faslodex (ICI 182,780), on estrogen-accelerated bone maturation in mice., Pediatr Res, 46, 269, 10.1203/00006450-199909000-00004 · DOI
  10. Mauras, 2000, Estrogen suppression in males: metabolic effects., J Clin Endocrinol Metab, 85, 2370
  11. Mauras, 1998, Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength and adiposity., J Clin Endocrinol Metab, 83, 1886
  12. Mauras, 1999, Profound hypogonadism has significant negative effects on calcium balance in males: a calcium kinetic study., J Bone Miner Res, 14, 577, 10.1359/jbmr.1999.14.4.577 · DOI
  13. Nelson, 2004, Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma., Clin Chem, 50, 373, 10.1373/clinchem.2003.025478 · DOI · Paper page
  14. Durnin, 1974, Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years., Br J Nutr, 32, 77, 10.1079/BJN19740060 · DOI · Paper page
  15. Steinberger, 2005, Comparison of body fatness measurements by BMI and skinfolds vs dual energy x-ray absorptiometry and their relation to cardiovascular risk factors in adolescents., Int J Obes (Lond), 29, 1346, 10.1038/sj.ijo.0803026 · DOI · Paper page
  16. Ibáñez, 2006, Metformin therapy during puberty delays menarche, prolongs pubertal growth, and augments adult height: a randomized study in low-birth-weight girls with early-normal onset of puberty., J Clin Endocrinol Metab, 91, 2068, 10.1210/jc.2005-2329 · DOI · Paper page
  17. Zachmann, 1978, Bayley-Pinneau, Roche-Wainer-Thissen, and Tanner height predictions in normal children and in patients with various pathologic conditions., J Pediatr, 93, 749, 10.1016/S0022-3476(78)81071-3 · DOI · Paper page
  18. Bramswig, 1990, Adult height in boys and girls with untreated short stature and constitutional delay of growth and puberty: accuracy of five different methods of height prediction., J Pediatr, 117, 886, 10.1016/S0022-3476(05)80127-1 · DOI
  19. Joss, 1992, Adult height in constitutionally tall stature: accuracy of five different height prediction methods., Arch Dis Child, 67, 1357, 10.1136/adc.67.11.1357 · DOI
  20. de Waal, 1996, Accuracy of final height prediction and effect of growth-reductive therapy in 362 constitutionally tall children., J Clin Endocrinol Metab, 81, 1206
  21. Bull, 1999, Bone age assessment: a large scale comparison of the Greulich and Pyle, and Tanner and Whitehouse (TW2) methods., Arch Dis Child, 81, 172, 10.1136/adc.81.2.172 · DOI · Paper page
  22. Hintz, 2001, Final height prediction in constitutional growth delay, J Pediatr Endocrinol Metab, 14, 1535
  23. Ranke, 2003, The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose., J Clin Endocrinol Metab, 88, 4748, 10.1210/jc.2003-030600 · DOI
  24. Mauras, 2004, An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys., J Pediatr Endocrinol Metab, 17, 1597, 10.1515/JPEM.2004.17.12.1597 · DOI · Paper page
  25. Klein, 1994, Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay., J Clin Invest, 94, 2475, 10.1172/JCI117616 · DOI · Paper page
  26. Plourde, 1994, Arimidex: a potent and selective fourth-generation aromatase inhibitor., Breast Cancer Res Treat, 30, 103, 10.1007/BF00682745 · DOI · Paper page
  27. Plourde, 1995, Arimidex: a new oral, once-a-day aromatase inhibitor., J Steroid Biochem Mol Biol, 53, 175, 10.1016/0960-0760(95)00045-2 · DOI
  28. Mauras, 2005, Are the metabolic effects of GH and IGF-I separable?, Growth Horm IGF Res, 15, 19, 10.1016/j.ghir.2004.12.003 · DOI
  29. Baroncelli, 1998, Measurement of volumetric bone mineral density accurately determines degree of lumbar undermineralization in children with growth hormone deficiency., J Clin Endocrinol Metab, 83, 3150, 10.1210/jcem.83.9.5072 · doi:10.1210/jcem.83.9.5072
  30. Hogler, 2005, Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency., Bone, 37, 642, 10.1016/j.bone.2005.06.012 · DOI
  31. Fewtrell, 2005, Dual x-ray absorptiometry (DXA) of the lumbar spine in a clinical paediatric setting: does the method of size-adjustment matter?, Bone, 37, 413, 10.1016/j.bone.2005.04.028 · DOI
  32. Lewiecki, 2006, Official positions of the International Society for Clinical Densitometry., Osteoporos Int, 17, 1700, 10.1007/s00198-006-0202-2 · doi:10.1007/s00198-006-0202-2
  33. Rosenfeld, 1995, Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited., J Clin Endocrinol Metab, 80, 1532
  34. Hilczer, 2006, Stability of IGF-I concentration despite divergent results of repeated GH stimulating tests indicates poor reproducibility of test results., Endocr Regul, 40, 37
  35. Anckaert, 2006, Variability among five different commercial IGF-1 immunoassays in conditions of childhood-onset GH deficiency and GH therapy., Acta Clin Belg, 61, 335, 10.1179/acb.2006.053 · doi:10.1179/acb.2006.053
  36. Casper, 2006, Aromatase inhibitors for ovulation induction., J Clin Endocrinol Metab, 91, 760, 10.1210/jc.2005-1923 · DOI · Paper page
  37. Reiter, 2005, Testotoxicosis: current viewpoint., Pediatr Endocrinol Rev, 3, 77
  38. Karmazin, 2005, The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function., J Pediatr Endocrinol, 18, 285, 10.1515/JPEM.2005.18.3.285 · DOI
  39. Mauras, 2003, A pharmacokinetics and dose finding of a potent aromatase inhibitor, Aromasinâ (Exemestane) in young males., J Clin Endocrinol, 88, 5951, 10.1210/jc.2003-031279 · DOI · Paper page

Cited by

See all 151

Metadata

Authors
Mauras, N., Gonzalez de Pijem, L., Hsiang, H. Y., Desrosiers, P., Rapaport, R., Schwartz, I. D., Klein, K. O., Singh, R. J., Miyamoto, A., & Bishop, K.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2008-03-01
Volume
93
Issue
3
Pages
823-831
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W1988888689
Cited by
151
References
9
FWCI
8.51
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.